Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Financial Officer | August 31, 2026 | September 01, 2026 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 22, 2023 | June 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 31, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,024 |
Ending reported balance
After 2026-08-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-31 · Exercise / conversion · Acquired 57,187 · Balance 176,798 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. Row 2 · 2026-08-31 · Sale · Disposed 23,072 · Balance 153,726 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-08-31 · Sale · Disposed 11,514 · Balance 142,212 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-08-31 · Sale · Disposed 28,188 · Balance 114,024 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.79 · Expires 2028-02-13 | Direct | 3,813 |
Reported balance
After 2026-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-31 · Exercise / conversion · Disposed 57,187 · Balance 3,813 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F5: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.
F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments.
Spyre Therapeutics, Inc.
Report date June 22, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-06-22 | Direct | 1,950,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 1,950,000 · Balance 1,950,000 F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENESEE & WYOMING INC
Report date December 30, 2019 · Filed December 30, 2019
Section 16 reporting ended · disclosed 2019-12-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common Stock, $.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-30 transaction · row 1
1 source rowRow 1 · 2019-12-30 · Disposition to issuer · Disposed 11,824 · Balance 0 F1: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration. F2: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration.
F2: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2023 Filed Jun 30, 2023 20:31 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantStock Option (right to buy) · Derivative | 1,950,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-23-040329 · doc4.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,950,000 Underlying: Common Stock · 1,950,000 shares Expires 2033-06-22 F1 · date: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-23-073327 · tm2319351-1_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,094 Underlying: Common Stock · 2,000 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,000 | $6.88 | $13,760.00 |
DisclosureSEC source: 0001104659-23-073327 · tm2319351-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 01:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 702 | $26.87 | $18,862.74 |
DisclosureSEC source: 0001104659-23-022112 · tm236871-8_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,406 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 15, 2023 01:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-022112 · tm236871-8_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,687 Underlying: Common Stock · 2,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2023 Filed Feb 15, 2023 01:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-022112 · tm236871-8_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-019830 · tm236605-5_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,187 Underlying: Common Stock · 4,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,398 | $27.66 | $38,668.68 |
DisclosureSEC source: 0001104659-23-019830 · tm236605-5_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,779 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-019830 · tm236605-5_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2023 Filed Feb 15, 2023 00:08 UTC Amendment | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,413 | $27.51 | $38,871.63 |
DisclosureSEC source: 0001104659-23-022062 · tm236871-1_4aseq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,764 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 53,600 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-23-010494 · tm235340-6_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2033-01-31 F3 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 19,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010494 · tm235340-6_4seq1.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,700 Underlying: Common Stock · 19,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 21:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-130967 · tm2233685-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,114 Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 22:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,547 | $4.08 | $30,791.76 |
DisclosureSEC source: 0001104659-22-077799 · tm2220562-1_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,614 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
| June 30, 2022 Filed Jul 6, 2022 22:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-077799 · tm2220562-1_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: On June 30, 2020, the Reporting Person was granted 25,000 restricted stock units, which vested in full on June 30, 2022. The restricted stock units have no expiration date. F3 · derivative.expiration_date: On June 30, 2020, the Reporting Person was granted 25,000 restricted stock units, which vested in full on June 30, 2022. The restricted stock units have no expiration date. Read SEC document |
| June 30, 2022 Filed Jul 6, 2022 22:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-077799 · tm2220562-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 01:19 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-22-035688 · doc4.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 00:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 833 | $6.10 | $5,081.30 |
DisclosureSEC source: 0001104659-22-023951 · tm226880-3_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,161 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023951 · tm226880-3_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,031 Underlying: Common Stock · 2,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-023951 · tm226880-3_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2022 Filed Feb 12, 2022 02:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 97,500 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-22-020896 · tm226394-7_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2032-02-08 F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 09, 2022 Filed Feb 12, 2022 02:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-020896 · tm226394-7_4seq1.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:34 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0001209191-21-064771 · doc4.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-11-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 36 equal monthly installments beginning on December 12, 2021 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 10:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-21-054045 · tm2113817-1_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,094 Underlying: Common Stock · 5,000 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 10:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,000 | $6.88 | $34,400.00 |
DisclosureSEC source: 0001104659-21-054045 · tm2113817-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:27 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 56,250 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001104659-21-024408 · tm216849-2_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2031-02-10 F3 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:27 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-024408 · tm216849-2_4seq1.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 9,375 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-21-005822 · tm213664-1_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,094 Underlying: Common Stock · 4,000 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,000 | $6.88 | $27,520.00 |
DisclosureSEC source: 0001104659-21-005822 · tm213664-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $22.53 | $0.00 |
DisclosureSEC source: 0001104659-20-085306 · a4.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-07-19 F1 · derivative.exercise_date: The stock options were granted on July 20, 2020. The option vests and becomes exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-080534 · a4.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · CFO and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest in full on June 30, 2022, provided that if the Reporting Person incurs a qualifying termination on or prior to June 30, 2022, the restricted stock units will vest in full immediately prior to such qualifying termination. The restricted stock units have no expiration date. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 22:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,900 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-20-041297 · a4.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · CFO and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,094 Underlying: Common Stock · 3,900 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018. Read SEC document |
| March 30, 2020 Filed Mar 31, 2020 22:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,900 | $6.88 | $26,832.00 |
DisclosureSEC source: 0001104659-20-041297 · a4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · CFO and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-20-034073 · a4.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,994 Underlying: Common Stock · 3,500 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,500 | $6.88 | $24,080.00 |
DisclosureSEC source: 0001104659-20-034073 · a4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:23 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 82,000 | $0.00 Strike: $17.87 | $0.00 |
DisclosureSEC source: 0001104659-20-022826 · a4.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 82,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2020 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 14, 2020. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 21:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-20-008015 · a4.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,494 Underlying: Common Stock · 6,250 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 21:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 6,250 | $6.88 | $43,000.00 |
DisclosureSEC source: 0001104659-20-008015 · a4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2019 Filed Dec 30, 2019 16:47 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | Disposition to issuerClass A Common Stock, $.01 par value | 11,824 | $112.00 | $1,324,288.00 |
DisclosureSEC source: 0001209191-19-062137 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration. F2 · kind: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger. F2 · shares: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger. F1 · price: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 17:44 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 166 | $110.67 | $18,371.22 |
DisclosureSEC source: 0001209191-19-051872 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,824 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Fourth Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-19-040345 · a4.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,744 Underlying: Common Stock · 10,000 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,000 | $6.88 | $68,800.00 |
DisclosureSEC source: 0001104659-19-040345 · a4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 16:26 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 307 | $98.57 | $30,260.99 |
DisclosureSEC source: 0001209191-19-040295 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,658 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Fourth Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| May 22, 2019 Filed May 24, 2019 17:22 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 1,161 | $86.07 | $99,927.27 |
DisclosureSEC source: 0001209191-19-032786 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,351 F1 · shares: This restricted stock award was granted under the Fourth Amended and Restated 2004 Omnibus Incentive Plan of Genesee & Wyoming Inc. (the "Company"). The shares subject to the restricted stock award will vest on the date of the next annual meeting of the Company. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 17:11 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 291 | $86.88 | $25,282.08 |
DisclosureSEC source: 0001209191-19-022652 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,190 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Fourth Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:10 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009044 · a4.xml · derivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-19-005511 · a4.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,744 Underlying: Common Stock · 3,000 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options were granted on August 9, 2017. 25% of the stock options vested and became exercisable on July 31, 2018. 75% of the stock options shall vest in 36 successive, equal monthly installments with the first such installment vesting and becoming exercisable on August 31, 2018. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,000 | $6.88 | $20,640.00 |
DisclosureSEC source: 0001104659-19-005511 · a4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 16:52 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 326 | $73.80 | $24,058.80 |
DisclosureSEC source: 0001209191-19-001058 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,899 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Fourth Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 17:12 UTC | GENESEE & WYOMING INC GWR · Entity 152834 | GrantClass A Common Stock, $.01 par value | 249 | $91.61 | $22,810.89 |
DisclosureSEC source: 0001209191-18-053287 · doc4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,573 F1 · shares: These are deferred stock units acquired pursuant to the deferred stock arrangements for non-employee directors in accordance with the terms of the Fourth Amended and Restated 2004 Omnibus Incentive Plan ("Omnibus Plan") of Genesee & Wyoming Inc. (the "Company"). The deferred stock units are converted into shares of the Company's Class A Common Stock on a one-for-one basis upon distribution. Distribution of shares of Class A Common Stock occurs the first day of the calendar month after a director's service on the Company's Board of Directors terminates or upon another date or dates designated by the director pursuant to the Omnibus Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.